- Regulus reports 1Q loss; also discloses workforce reduction of 30%, CEO resigns
SAN DIEGO (AP) _ Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $20 million in its first quarter.
The San Diego-based company said it had a loss of 38 cents per share.
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 33 cents per share.
The biopharmaceutical company posted revenue of $18,000 in the period.
The company's shares closed at $1.70. A year ago, they were trading at $5.39.
No comments:
Post a Comment